Ionizable Lipid Products
Explore 848 lipid and RNA delivery products. Search the full catalog or browse by research category.
Search covers product name, catalog number, synonyms, available CAS numbers and categories. Spaces, hyphens and common punctuation are ignored. Duplicate legacy records are consolidated under one canonical product result.
Built for ionizable-lipid discovery and RNA delivery research
DC Chemicals supports formulation and delivery research with a broad, searchable portfolio of cationic and ionizable lipids. The current directory brings together 848 unique research-use products, with product specifications, pricing, chemical structures and literature-linked formulation data added as each record is verified.
Our experience spans complex lipid synthesis, purification, analytical release and process development. For custom molecules or larger-scale requirements, our team can discuss route development, technical specifications and scale-up options for the intended research workflow.
Learn about cationic and ionizable lipids →From proprietary lipid design to GMP-grade custom synthesis
DC Chemicals has independently developed ionizable-lipid structures supported by company-owned intellectual property, and selected proprietary lipid programs have advanced to GMP-stage development.
We welcome joint development with customers—from molecular design and lipid synthesis through route and process development. We can also support custom synthesis of GMP-grade ionizable lipids to agreed technical specifications and quality requirements.
Discuss a co-development project →Explore New ionizable lipids
Explore our five most recently added ionizable lipids, with specifications, pricing and literature-linked product information.
A potent integrin αvβ3 antagonist with IC50 of 18 nM; could be conjugated to paclitaxel for selective delivery to alphavbeta3 positive metastatic cancer cells.
A potent inhibitor of HIV-1 integrase-LEDGF/p75 interaction; binds to IN and IN(T125A) with Kd of 5.81 and 15.2 uM; affects the HIV-1 IN nuclear distribution thus exhibiting antiretroviral activity.HIV InfectionPreclinical
A potent inhibitor of HDAC1/3/6 with IC50s of 43-72 nM; induces hyperacetylation of histone H4 and apoptosis in MM cell lines (IC50=2.5-3 uM); decreases levels of cyclin D1, cdc25a, Cdk4 and pRb as well as upregulation of p21; downregulates phosphorylation of 4E-BP1 and p70S6k.Liver CancerPhase 2 Clinical
A potent histamine 1 receptor antagonist.
A potent dopamine D2 receptor antagonist with Ki of 28 nM; also is a mixed 5-HT3 receptor antagonist/5-HT4 receptor agonist; commonly used to treat nausea and vomiting caused by chemotherapy.Chemotherapeutic AgentsPhase 2 Discontinued
A potent dopamine D2 receptor antagonist with Ki of 28 nM; also is a mixed 5-HT3 receptor antagonist/5-HT4 receptor agonist; commonly used to treat nausea and vomiting caused by chemotherapy.Chemotherapeutic AgentsPhase 2 Discontinued
A potent and selective VEGFR2 (KDR) inhibitor with IC50 of 40 nM; shows weak inhibition for VEGFR3 and EGFR (IC50 is 100 nM and 500 nM respectively); displays excellent selectivity over erbB2, MEK, CDK-2, Tie-2, IGFR-1R, PDK, PDGFRβ, and Akt (IC50=1.1-100 uM); has excellent solubility and good oral bioavailability.Thyroid CancerApproved
A potent and selective dopamine D3 receptor antagonist with pKi of 8.0; displays >100-fold selectivity against the D2, 5-HT1B, and 5-HT1D receptors; exhibits high oral bioavailability and brain penetration in rats.SchizophreniaDiscontinued
A potent and selective antagonist of H3 receptor with Ki/EC50 of 0.16/1.5 nM; no effect on H1, H2, H4 receptors (IC50>10 uM); orally bioactive.Sleep DisorderApproved
A plant flavonoid that has been found to inhibit cell proliferation by arresting the cell cycle at the G2/M phase. Inhibition of growth through cell cycle arrest and induction of apoptosis appear to be related to induction of p53.Inhibits PMA-mediated tumor promotion by inhibiting protein kinase C1 and the resulting suppression of oncogene expression. It has also been reported to inhibit topoisomerase I-catalyzed DNA re-ligation and enhance gap junctional intercellular communication.
A plant activator of systemic acquired resistance, boosts the production of herbivore-induced plant volatiles; insecticide agent.
A novel, highly potent inhibitor of the FabI enzyme of both Staphylococcus aureus and Escherichia coli; shows activity against S. aureus strains, including MSSA, MRSA, linezolid-resistant, and multidrug-resistant strains with MIC90s of 0.03-0.12 ug/ml; also has active against coagulase-negative staphylococci with MIC90s of 0.12-4 ug/ml; active in vivo (19.3-49.6 mg/kg/day).Bacterial InfectionPreclinical
A novel potent, selective Sirt2 inhibitor with IC50 of 3.745 uM; displays no inhibitory activity against Sirt1 and Sirt 3 (IC50>100 uM).
A novel orally available, synthetic retinoid with potential antineoplastic and chemopreventive activities; inhibits DEN-induced rat hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation; decreases the levels of cyclin D1, cyclin D2, cIAP2 and XIAP proteins, and inhibits growth of ATL cells both in vitro and in vivo; prevents the progression of NASH and the development of HCC through activating the autophagy pathway by increased Atg16L1 expression in mice model; also inhibits HCV replication and infectious virus release in vitro.Liver CancerPhase 3 Clinical
A novel isocitrate lyase (ICL) inhibitor that displays showed excellent anti-Mycobacterium tuberculosisl activities and low cytotoxicity; shows good activity against M. tuberculosis H37Ra with MIC of 0.5 ug/ml; significantlt reduces bacterial loads of both lungs and spleen in a murine model.Bacterial InfectionPreclinical
A novel hypoxia-sensitive fluorescent probe; has good solubility in water and longer wavelength for absorption and emission, which are favorable for cellular bioimaging.
A novel and irreversible inhibitor of mutant K-ras G12C.
A novel and irreversible inhibitor of mutant K-ras G12C.
A nootropic agent that enhances high-affinity choline uptake; significantly improves the learning deficits in the Morris' water maze of AF64A-treated rats, do not produce any significant side effects (1-10 mg/kg); orally active.Alzheimer's DiseasePhase 2 Discontinued
A multichannel blocker agent that has antiarrhythmic activity; reduces the late sustained K(+) current, I(K) (or Isus) with EC50 of 0.85 uM in postmyocardial infarcted (PMI) rats; reduces significantly the incidence of ventricular fibrillation (VF) in rats; mainly used for treatment of cardiac arrhythmias.Heart ArrhythmiaApproved
Page 315 of 334 · Browse all 6677 products
Jump to a product page
Featured literature product: HX1 · DCL0028
HX1 is a hydroxyzine-derived ionizable lipid with acetal-containing tails, studied in lipid nanoparticles for brain mRNA delivery and CRISPR–Cas9 delivery. It was the lead in the reported in vivo brain-delivery screen; evidence is preclinical and formulation-dependent.
Read full formulation and performance →